TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30895697

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily in addition to standard care
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo in addition to standard care
Number of subjects: 4744
Study: 27838760

Group type: EXPERIMENTAL
Intervention: SIDCER informed consent form (ICF)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Conventional informed consent form (ICF)
Number of subjects: 258
Study: 27325392

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT) + Contingency Management (CM)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT) alone
Number of subjects: 159
Study: 24535100

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 23090521

Group type: EXPERIMENTAL
Intervention: Antibiotic administration
Number of subjects: 161

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 161
Study: 19527368

Group type: EXPERIMENTAL
Intervention: Standard treatment for osteolymphoma (chemotherapy and radiotherapy)
Number of subjects: 25
Study: 16430566

Group type: EXPERIMENTAL
Intervention: Target controlled propofol 3 microg.ml(‐1) infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane 1‐1.2% in air
Number of subjects: 40
Study: 14679434

Group type: EXPERIMENTAL
Intervention: Cemented group with polished Landos Fjord‐CrCo stems
Number of subjects: 14

Group type: COMPARATOR
Intervention: Uncemented group with hydroxyapatite‐coated Landos Corail‐Titan stems
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (Cemented and Uncemented)
Number of subjects: 14
Study: 11128729

Group type: EXPERIMENTAL
Intervention: Rehabilitation at home by rehabilitation team for up to three months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study: 9377859

Group type: EXPERIMENTAL
Intervention: Propranolol at a dose of 240 mg/day for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold pressor test (CPT) before beta-blockade
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 20
Study: 1543450

Group type: EXPERIMENTAL
Intervention: Topical 1% indomethacin aqueous suspension
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 36
Study: 3920393

Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 120
Study: 31259767

Group type: EXPERIMENTAL
Intervention: Overall HIV stigma
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Enacted stigma (between-subject)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Enacted stigma (within-subject)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 234
Study: 29176500

Group type: EXPERIMENTAL
Intervention: Active cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study: 27433837

Group type: EXPERIMENTAL
Intervention: D-002 (50 mg/d)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D-003 (10 mg/d)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D-002/D-003 (50 mg/d of D-002 plus 10 mg/d of D-003)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D-002
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D-003
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D-002/D-003
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 24867622

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 52

Group type: COMPARATOR
Intervention: Basic intervention
Number of subjects: 52
Study: 22998742

Group type: EXPERIMENTAL
Intervention: Combination of buspirone 15 mg and melatonin-SR 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone 15 mg monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20648928

Group type: EXPERIMENTAL
Intervention: 100 mg iron as FCM given as an i.v. bolus injection
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 500 mg iron as FCM given as an i.v. infusion over 15 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 800 mg iron as FCM given as an i.v. infusion over 15 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1000 mg iron as FCM given as an i.v. infusion over 15 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18382126

Group type: EXPERIMENTAL
Intervention: Multimarker real-time RT-PCR methodology for quantification of five melanoma markers (Melan-A, gp 100, MAGE-3, MIA, tyrosinase)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MAGE-3 as a progression marker
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Multimarker real-time RT-PCR
Number of subjects: 65
Study: 15819586

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel for 12 months after PCI with DES
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel for 4 weeks plus aspirin after PCI with DES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined antithrombotic therapy with aspirin and clopidogrel
Number of subjects: 0
Study: 14517641

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 67
Study: 10626025

Group type: EXPERIMENTAL
Intervention: Involvement in decision-making about testing for recurrent disease (TFR) as part of follow-up care
Number of subjects: 0
Study: 9005786

Group type: EXPERIMENTAL
Intervention: Oral administration of ofloxacin 400 mg once a day (group I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous administration of ofloxacin 200 mg twice a day for 2 to 4 days followed by oral use of 400 mg once a day for 6 to 8 days (group II)
Number of subjects: 24
Study: 1930700

Group type: EXPERIMENTAL
Intervention: Herbal ingredients in toothpaste and oral rinse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo preparations
Number of subjects: 50
Study: 7074749

Group type: EXPERIMENTAL
Intervention: Flecainide acetate (average daily dose 436 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flecainide therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flecainide therapy after 1 week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flecainide therapy after 2 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flecainide concentrations of 200‐800 ng/ml
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flecainide acetate
Number of subjects: 11
Study: 31402072

Group type: EXPERIMENTAL
Intervention: ARM-ALND
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-ALND
Number of subjects: 0
Study: 31291207

Group type: EXPERIMENTAL
Intervention: cCBT program 'Good Days Ahead' with weekly guidance and support
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control condition with a freely available online CBT workbook
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: cCBT program 'Good Days Ahead'
Number of subjects: 67
Study: 29051015

Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention (Supporting Children's Outcomes using Rewards, Exercise and Skills) over 6 months.
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1139
Study: 25357093

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 78
Study: 22837541

Group type: EXPERIMENTAL
Intervention: Group-based functional and specific balance training programme including dual-task exercises (24 training sessions over three months)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Reference group (no intervention)
Number of subjects: 66
Study: 21871427

Group type: EXPERIMENTAL
Intervention: Recombinant MMP‐3
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMP‐3-null mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purified MMP‐3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bleomycin-treated MMP‐3-null mice
Number of subjects: 0
Study: 19552232

Group type: EXPERIMENTAL
Intervention: Xylitol gum (4.2 gm/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sorbitol gum (4.2 gm/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 97

Group type: COMPARATOR
Intervention: Xylitol gum (6 months after baseline exams)
Number of subjects: 97
Study: 17353581

Group type: COMPARATOR
Intervention: Upper tertile of diet score (mean diet score 26.3 ± 6.8 in normoglycemic, 25.7 ± 6.4 in IFG, 22.2 ± 5.8 in diabetic subjects)
Number of subjects: 3042

Group type: COMPARATOR
Intervention: Upper tertile of diet score
Number of subjects: 3042
Study: 12653894

Group type: EXPERIMENTAL
Intervention: Phenobarbital (150 mg) for 7 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Phenobarbital (150 mg) for 7 days in subgroup IB (n = 22)
Number of subjects: 46
Study: 10591823

Group type: EXPERIMENTAL
Intervention: Ondansetron orally disintegrating tablet (ondODT) 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron orally disintegrating tablet (ondODT) 16 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8877126

Group type: EXPERIMENTAL
Intervention: 15-, 45-, or 135-micrograms doses of monovalent influenza A/Taiwan (H1N1) hemagglutinin (HA) vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15-, 45-, or 135-micrograms doses of subvirion (SV) vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1816396

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Gentamicin/Clindamycin
Number of subjects: 97
Study: 6210562

Group type: EXPERIMENTAL
Intervention: Mezlocillin 1 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mezlocillin 3 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mezlocillin 5 g
Number of subjects: 12
Study: 31992258

Group type: EXPERIMENTAL
Intervention: 12-session continuing care telephone intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-session continuing care telephone intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: continuing care plan only
Number of subjects: 0
Study: 30694322

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (cumulative dose, 72.5 mg/kg)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 372
Study: 29178895

Group type: EXPERIMENTAL
Intervention: Joint Crisis Plans
Number of subjects: 221

Group type: COMPARATOR
Intervention: Routine care plans
Number of subjects: 221
Study: 25240300

Group type: EXPERIMENTAL
Intervention: Contagious yawning elicited through viewing videotaped yawn stimuli
Number of subjects: 14
Study: 23701917

Group type: EXPERIMENTAL
Intervention: GSK256066 25 μg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: GSK256066 87.5 μg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 21986180

Group type: EXPERIMENTAL
Intervention: Sodium glycerophosphate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sodium phosphate
Number of subjects: 27
Study: 19595367

Group type: EXPERIMENTAL
Intervention: Parent Baby Interaction Programme (PBIP) sessions during neonatal intensive care unit admission and up to 6 weeks after discharge
Number of subjects: 233

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 233
Study: 16757200

Group type: EXPERIMENTAL
Intervention: Intraoral fluoride-releasing system (IFRS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Stannous fluoride gel (control group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (stannous fluoride gel)
Number of subjects: 22
Study: 14988783

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% and tropicamide 1% eye-drops
Number of subjects: 303

Group type: COMPARATOR
Intervention: No mydriatics
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% plus epinephrine 1/200,000
Number of subjects: 303
Study: 10512253

Group type: EXPERIMENTAL
Intervention: Dopamine (DOA) 5 microg x kg(‐1) x min(‐1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dobutamine (DOB) 0.5, 1, or 3 microg x kg(‐1) x min(‐1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dopamine (DOA) and Dobutamine (DOB)
Number of subjects: 70
Study: 7481985

Group type: EXPERIMENTAL
Intervention: Very-low-intensity anticoagulation (INR 1.4 to 2.0)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard low-intensity anticoagulation (INR 2.0 to 3.0)
Number of subjects: 101
Study: 1772463

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d. for 24 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 7338121

Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study: 31589066

Group type: EXPERIMENTAL
Intervention: Visual processing of tetrominoes in a stream of distracting objects.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Visual processing of tetrominoes with incidental shape information.
Number of subjects: 7
Study: 30680452

Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 mg
Number of subjects: 200
Study: 29864379

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 452

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 452

Group type: COMPARATOR
Intervention: Dacomitinib vs Gefitinib
Number of subjects: 452
Study: 27138789

Group type: EXPERIMENTAL
Intervention: 25(OH)D (≥30 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D
Number of subjects: 0

Group type: COMPARATOR
Intervention: UDCA
Number of subjects: 0
Study: 25132143

Group type: EXPERIMENTAL
Intervention: Combination therapy of 400 mg oral zinc sulfate with podophyllin
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Combination therapy of 400 mg oral zinc sulfate with imiquimod
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Combination therapy of 400 mg oral zinc sulfate with cryotherapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Podophyllin alone
Number of subjects: 228

Group type: COMPARATOR
Intervention: Imiquimod alone
Number of subjects: 228

Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 228
Study: 22035976

Group type: EXPERIMENTAL
Intervention: Collagen/thrombin and autologous platelet hemostatic agent (standard hemostasis plus study product)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard hemostasis alone (control)
Number of subjects: 100
Study: 19529944

Group type: EXPERIMENTAL
Intervention: Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision trees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SELDI-TOF MS for beta-hCG-negative seminomas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 17611335

Group type: EXPERIMENTAL
Intervention: 10microg/kg fentanyl (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1microg/kg sufentanil (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5microg/kg sufentanil (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5microg/kg sufentanil (Group D)
Number of subjects: 60
Study: 16130582

Group type: EXPERIMENTAL
Intervention: Pram walking group (intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not participating in pram walking group)
Number of subjects: 60
Study: 12152252

Group type: EXPERIMENTAL
Intervention: 75 mg/day p.o. aspirin for 3 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 300 mg/day p.o. aspirin for 3 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9917118

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 7549815

Group type: EXPERIMENTAL
Intervention: Awareness of breast cancer risk education
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Demographic factors (unmarried status)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Education level (high school or less)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Ethnicity (African American vs. White)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Logistic regression predictors
Number of subjects: 395
Study: 30669202

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250mg/day + Budesonide nasal spray once a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Budesonide nasal spray once a day
Number of subjects: 80
Study: 28670911

Group type: COMPARATOR
Intervention: Exelon (reference)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rivastigmine (test)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rivastigmine/Exelon
Number of subjects: 40
Study: 25453593

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12 daily exposures to vegetable puree added to milk (days 1-12), then 12 x 2 daily exposures to vegetable puree added to rice (days 13-24)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group (CG) - Plain milk and rice given, followed by 11 daily exposures to vegetable puree
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups received 11 daily exposures to vegetable puree after initial interventions
Number of subjects: 36
Study: 23739785

Group type: EXPERIMENTAL
Intervention: 1.23% APF gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 21476457

Group type: EXPERIMENTAL
Intervention: Prosocial video games
Number of subjects: 0

Group type: COMPARATOR
Intervention: Violent video games
Number of subjects: 0
Study: 19636603

Group type: EXPERIMENTAL
Intervention: Watercress extract (WCE) 0.1-10 microL/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenethyl isothiocyanate (PEITC) 1-10 microM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Watercress consumption (85 g per day for 8 weeks)
Number of subjects: 0
Study: 15497672

Group type: EXPERIMENTAL
Intervention: Test formulation (Seralin)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 11580001

Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment (6 months or more)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depot antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 0
Study: 11301561

Group type: EXPERIMENTAL
Intervention: (R)-albuterol 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (S)-albuterol 1.25 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (R)-albuterol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (RS)-albuterol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (R)-albuterol and (RS)-albuterol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (S)-albuterol
Number of subjects: 15
Study: 8148281

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) 5 mg/kg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous reducing dose of CyA (1 mg/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent fixed dose of CyA (5 mg/kg every fifth day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 24
Study: 3211287

Group type: EXPERIMENTAL
Intervention: oral scopolamine 0.3 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oral scopolamine 0.6 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oral scopolamine 1.2 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oral methylscopolamine 0.6 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 29754829

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 56
Study: 25942015

Group type: EXPERIMENTAL
Intervention: 40-Hz WBV at higher amplitude (2-3 mm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 40-Hz WBV at lower amplitude (1-2 mm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No WBV (NV)
Number of subjects: 16
Study: 25809183

Group type: EXPERIMENTAL
Intervention: Short stem
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard stem
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23044919

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 28
Study: 20587350

Group type: EXPERIMENTAL
Intervention: Platycarya strobilacea fruit extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ellagic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test product (P. strobilacea extract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18261569

Group type: EXPERIMENTAL
Intervention: Single low-dose anti-thymocyte globulin (ATG) prophylaxis (4-5 mg/kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (cyclosporine, mycophenolate mofetil or azathioprine, and prednisolone)
Number of subjects: 68
Study: 16096664

Group type: EXPERIMENTAL
Intervention: Trypan blue staining under air
Number of subjects: 52

Group type: COMPARATOR
Intervention: Trypan blue staining under viscoelastic
Number of subjects: 52